ArticleThe American journal of surgical pathology2016
Neuroendocrine Carcinoma of the Endometrium: A Clinicopathologic Study of 25 Cases.
Article in The American journal of surgical pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 125 citations in OpenAlex.
- Pathological processes and pretreatment cytologic diagnosis of neuroendocrine carcinoma of the endometrium: addendum report of the Kansai Clinical Oncology Group/Intergroup study in Japan.Medical molecular morphology · 2021Trial
- Primary pure small cell neuroendocrine carcinoma of the endometrium: a case report.Journal of medical case reports · 2026Article
- Article
- Case Report: A Case of Neuroendocrine Carcinoma of the Endometrium with Deficient DNA Mismatch Repair Had Achieved Clinical Complete Response after Combination Therapy.Oncology research · 2026Article
- Neuroendocrine Tumors of the Endometrium: a Case Series with Clinico-Pathological Analysis and Review of Literature.Indian journal of surgical oncology · 2025Article
- PAX8 expression in cancerous and non-neoplastic tissue: a tissue microarray study on more than 17,000 tumors from 149 different tumor entities.Virchows Archiv : an international journal of pathology · 2024Article
- Endometrial large cell neuroendocrine carcinoma: A case report and literature review.Gynecologic oncology reports · 2024Article
- Neuroendocrine carcinoma of the endometrium: a retrospective analysis of data from a single center.BMC cancer · 2024Article
- Uncommon Morphologic Types of Endometrial Cancer and Their Mimickers: How Much Does Molecular Classification Improve the Practice for Challenging Cases?Life (Basel, Switzerland) · 2024Review
- Diagnostic and therapeutic challenge of neuroendocrine endometrial carcinoma: a case report.The Pan African medical journal · 2024Article
- Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives.Journal of clinical medicine · 2023Review
- Neuroendocrine carcinoma of the endometrium concomitant with Lynch syndrome: A case report.World journal of clinical cases · 2023Article
- Mixed high-grade serous and large cell neuroendocrine carcinoma arising from rectal endometriosis 11 years after hysterectomy.Clinical journal of gastroenterology · 2023Article
- Metastasis to Thyroid Gland from Neuroendocrine Carcinoma of Endometrium: A Rare Entity.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023Article
- A Hypoxia Molecular Signature-Based Prognostic Model for Endometrial Cancer Patients.International journal of molecular sciences · 2023Article
- Neuroendocrine Tumor of the Fallopian Tube and Serous Adenocarcinoma of the Ovary: Multicentric Primary Tumors.Turk patoloji dergisi · 2023Article
- Whole exome sequencing identifies common mutational landscape of cervix and endometrium small cell neuroendocrine carcinoma.Frontiers in oncology · 2023Article
- A case of primary small cell neuroendocrine carcinoma of the uterus.Radiology case reports · 2022Article
- The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review.Cancers · 2022Review
- Clinical characteristic and prognostic factors in high-grade endometrial neuroendocrine carcinoma.The journal of obstetrics and gynaecology research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Neuroendocrine carcinoma (NECa) of the endometrium is an uncommon tumor. In this study, we present the clinicopathologic features of 25 such cases. The patients ranged in age from 37 to 87 years (median, 57 y) and most commonly presented with vaginal bleeding. The tumors were either pure NECa (10) or mixed with other histotypes (15), most commonly endometrioid carcinoma. The NECas were large cell type (15), small cell type (4), or a mixture of both (6). NECa was underrecognized in 89% of referral/consultation cases. All tumors were positive for ≥1 neuroendocrine marker (chromogranin, synaptophysin, CD56). Additional immunohistochemical (IHC) studies were obtained in 18 cases, with positive results as follows: keratin cocktail (17), diffuse p16 (6), PAX-8 (6), CD117 (6), and TTF-1 (1). Mismatch-repair protein expression by IHC was abnormal in 8 of 18 cases (6 MLH1/PMS2 loss; 1 MSH2/MSH6 loss; 1 MSH6 loss). According to FIGO staging, cases were distributed as follows: I (6), II (2), III (10), and IV (7). All patients underwent surgical treatment, and 20 patients received adjuvant therapy. Twelve patients died of disease (mean survival 12.3 mo). Eleven patients were alive 5 to 134 months after diagnosis, including 7 who achieved a 5-year survival (3 stage I; 4 stage III). In summary, most of our endometrial NECas were large cell type, mixed with other histotypes, and underrecognized. These tumors tend to be PAX-8 negative and may be associated with microsatellite instability. The recognition of NECa may have an impact on the treatment of the patients affected by this disease. Although NECa usually has an aggressive behavior, 28% of our patients survived at least 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.